Last updated: February 26, 2026
What is NDC 00781-5641?
NDC 00781-5641 corresponds to Rituximab (brand: Rituxan), a monoclonal antibody used to treat certain cancers and autoimmune diseases. It is FDA-approved for multiple indications, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and more.
Market Overview
Market Size and Growth Drivers
- The global rituximab market was valued at approximately USD 7.8 billion in 2022.
- Compound annual growth rate (CAGR) estimated at 5.2% from 2023 to 2028.[1]
- Key growth factors include increased prevalence of autoimmune diseases, expanding indications, improved survival rates, and biosimilar entries.
Competitive Landscape
- Major players: Genentech (Roche), Sandoz (Novartis), Teva, Dr. Reddy’s Laboratories.
- Biosimilar entries have increased competition, notably:
| Biosimilar |
Approval Year |
Market Share (2022) |
Price Reduction Post-Entry |
| Truxima |
2018 |
8% |
20-30% lower than reference |
| Ruxience |
2019 |
4% |
25-35% lower than reference |
- Original biologic (Rituxan) maintains dominance but faces price pressure from biosimilars.
Regulatory Environment
- The Biologics Price Competition and Innovation Act (2009) facilitates biosimilar approval, which influences market dynamics.
- Recent approval of biosimilars in the U.S. and EU targets price reduction.
Price Analysis & Projections
Current Pricing
- U.S. average wholesale price (AWP): approximately USD 4,200 per vial.
- Typical treatment course (4-8 infusions) can cost USD 15,000–USD 33,600 depending on dosage and frequency.
- Rx reimbursement varies based on insurance and biosimilar competition.
Pricing Trends
- Biosimilars reduce prices by 20-35% within the first two years of market entry.
- Original biologics may retain higher list prices but face discounts in actual sales.
Projected Price Dynamics (2023–2028)
| Year |
Reference (Rituxan) Price |
Biosimilar Price Range |
Expected Discount |
Notes |
| 2023 |
USD 4,200 per vial |
USD 2,800–3,400 |
20–33% |
Entry of additional biosimilars stabilizes prices. |
| 2024 |
USD 4,150 per vial |
USD 2,750–3,350 |
21–34% |
Increased biosimilar competition further moderates pricing. |
| 2025 |
USD 4,100 per vial |
USD 2,700–3,300 |
22–34% |
Market shift toward biosimilar dominance. |
| 2026 |
USD 4,050 per vial |
USD 2,650–3,250 |
23–34% |
Steady competition maintains downward pricing pressure. |
| 2027 |
USD 4,000 per vial |
USD 2,600–3,200 |
24–35% |
Biosimilar market share peaks at approximately 25%. |
Volume and Revenue Projections
- Estimated annual demand increasing at 4–6%, driven by expanding indications.
- Total revenue for rituximab therapies expected to reach USD 8–10 billion globally by 2028.
- Biosimilar uptake could displace up to 50% of reference biologic sales in mature markets by 2027.
Regulatory and Market Barriers
- Patent expirations for original formulations mainly occurred around 2018–2019.
- Patent litigations and exclusivity periods (e.g., 12-year exclusivity in the U.S.) delay biosimilar entry.
- Market penetration varies based on healthcare policies, reimbursement systems, and clinician acceptance.
Strategic Implications
- Investors should monitor biosimilar approvals and market share evolution.
- Opportunities exist in biosimilar manufacturing, distribution, and biosimilar-dedicated therapies.
- Price erosion is likely to plateau once biosimilar market penetration reaches 40–50%.
Key Takeaways
- The rituximab market is mature, with high competition from biosimilars driving prices downward.
- Prices are forecasted to decline further, with a 20–35% reduction in list prices over the next five years.
- Revenue growth depends on expanding indications and biosimilar adoption.
- Regulatory landscape remains critical, with patent protections and approval pathways influencing market entry.
- Strategic positioning should consider biosimilar market share and healthcare policies affecting pricing and reimbursement.
FAQs
1. What factors most influence the price of NDC 00781-5641?
Biosimilar competition, patent expirations, manufacturing costs, and healthcare reimbursement policies.
2. How do biosimilars impact the price of Rituxan?
They typically reduce prices by 20–35%, increasing market competition and lowering consumer costs.
3. What is the expected timeline for further price reductions?
Biosimilar entry has caused steady price reductions since 2018; significant decreases are expected through 2025–2026.
4. Are there upcoming regulatory changes that could affect the market?
Potential patent litigations, biosimilar approvals, and policy reforms in the U.S. and EU could alter market dynamics.
5. How does the increase in indications affect the market?
Broader indications increase demand and revenue potential but can also lead to more biosimilar competition.
References
[1] MarketWatch. (2023). Global Rituximab Market Size, Share & Industry Trends. Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). Biosimilar Approval and Market Penetration Data.
[3] U.S. Food and Drug Administration. (2022). Biosimilar Product Development.
[4] Pharma Intelligence. (2023). Oncology Market Dynamics.
